With highly specialized testing technologies—including next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), and fluorescence in situ hybridization (FISH)—we can help you get answers you can trust so you can make more informed decisions for patient care.
Comprehensive precision oncology testing menu
Our comprehensive, guideline-driven panels deliver insights to help you make treatment decisions based on the mutations found in the individual’s tumor sample. These panels can be helpful in determining eligibility in clinical studies.
We also offer individually orderable tests for certain components of the panels where you need specific insight for a patient.
Solid TumorSEQ™ and LiquidSEQ™ provide tissue and liquid biopsy solutions for comprehensive genomic profiling, including 523 genes associated with a broad spectrum of solid tumor cancers, assessing single nucleotide variants (SNVs), copy number variants (CNVs), fusions, and splice variants along with genomic signatures, microsatellite instability (MSI), and tumor mutation burden (TMB).
